专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010045624A1 INHIBITORS OF MITOSIS FOR INCREASING APOPTOSIS IN THERAPY 审中-公开
标题翻译： MITOSIS抑制剂治疗药物治疗药物
公开(公告)号：WO2010045624A1
公开(公告)日：2010-04-22
申请号：PCT/US2009/061106
申请日：2009-10-16
申请人： ARRAY BIOPHARMA INC. , TUNQUIST, Brian, J. , WALKER, Duncan, H. , WOESSNER, Richard, Donald
发明人： TUNQUIST, Brian, J. , WALKER, Duncan, H. , WOESSNER, Richard, Donald
IPC分类号： A61K31/433 , A61P35/00
CPC分类号： A61K31/433
摘要： An inhibitor of mitosis for administration to a patient having pathogenic cells in a state of mitosis inhibitor-induced mitotic arrest, for increasing apoptosis of the cells.
摘要翻译：有丝分裂抑制剂用于给予具有有丝分裂抑制剂诱导的有丝分裂停滞状态的病原体的患者，用于增加细胞凋亡。

2. 发明申请

WO2005016381A2 COMBINATION THERAPY FOR THE TREATMENT AND PREVENTION OF CANCER USING EPHA2, PCDGF, AND HAAH 审中-公开
标题翻译：使用EPHA2，PCDGF和HAAH治疗和预防癌症的联合治疗
公开(公告)号：WO2005016381A2
公开(公告)日：2005-02-24
申请号：PCT/US2004/023097
申请日：2004-07-16
申请人： MEDIMMUNE, INC. , KINCH, Michael, S. , CARLES-KINCH, Kelly , KIENER, Peter , LANGERMANN, Solomon , MCCARTHY, Michael, P. , TICE, David , WOESSNER, Richard
发明人： KINCH, Michael, S. , CARLES-KINCH, Kelly , KIENER, Peter , LANGERMANN, Solomon , MCCARTHY, Michael, P. , TICE, David , WOESSNER, Richard
IPC分类号： A61K39/395
CPC分类号： C07K16/40 , A61K39/39558 , A61K2039/505 , C07K16/3076 , C07K2317/73 , C07K2317/75 , C07K2317/80 , A61K2300/00
摘要： The present invention relates to methods and compositions designed for the treatment, management, or prevention of a hyperproliferative disorder, particularly cancer, more particularly metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more agents that decrease/inhibit EphA2 expression or activity in combination with one or more agents that decrease/inhibit PCDGF or HAAH expression or activity. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2, PCDGF, and/or HAAH agents of the invention that inhibit cancer cell colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparation. The invention also provides pharmaceutical compositions comprising one or more EphA2 agents of the invention in combination with one or more PCDGF agents of the invention and/or one or more HAAH agents of the invention. In some embodiments, the agents of the invention can be administered with other cancer therapeutic agents that are not EphA2-, PCDGF-, or HAAH-based. Diagnostic methods and methods for screening for therapeutically useful agents of the invention are also provided.
摘要翻译：本发明涉及设计用于治疗，控制或预防过度增殖性疾病，特别是癌症，特别是转移性癌症的方法和组合物。本发明的方法包括给予一种或多种降低/抑制EphA2表达或活性的一种或多种与减少/抑制PCDGF或HAAH表达或活性的一种或多种试剂组合的试剂。在另一个实施方案中，本发明的方法包括施用有效量的本发明的一种或多种EphA2，PCDGF和/或HAAH剂，其抑制在三维基底中的软琼脂或管状网络形成中的癌细胞集落形成膜或细胞外基质制剂。本发明还提供包含本发明的一种或多种EphA2试剂与本发明的一种或多种PCDGF试剂和/或本发明的一种或多种HAAH试剂组合的药物组合物。在一些实施方案中，本发明的药剂可以与不是EphA2-，PCDGF-或HAAH的其它癌症治疗剂一起施用。还提供了用于筛选本发明的治疗有用的药剂的诊断方法和方法。

3. 发明申请

WO2003075957A1 THE PREVENTION OR TREATMENT OF CANCER USING INTEGRIN ALPHAVBETA3 ANTAGONISTS IN COMBINATION WITH OTHER AGENTS 审中-公开
标题翻译：使用INTEGRIN ALPHAVBETA3拮抗剂与其他药物联合治疗癌症的预防或治疗
公开(公告)号：WO2003075957A1
公开(公告)日：2003-09-18
申请号：PCT/US2003/006684
申请日：2003-03-04
申请人： MEDIMMUNE, INC. , WOESSNER, Richard , KIENER, Peter , DORMITZER, Melissa , WALSH, William , HEINRICHS, Jon
发明人： WOESSNER, Richard , KIENER, Peter , DORMITZER, Melissa , WALSH, William , HEINRICHS, Jon
IPC分类号： A61K39/395
CPC分类号： A61K31/565 , A61K31/59 , A61K38/23 , A61K45/06 , A61K47/64 , A61K2039/505 , C07K16/2848 , G01N33/574 , G01N33/68 , G01N2333/70546 , A61K2300/00
摘要： The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more antagonists of Integrin α V β 3 alone or in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more antagonists of Integrin α V β 3 and/or one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of a therapeutically or prophylactically effective amount of one or more antagonists of Integrin α V β 3 alone or in combination with standard and experimental therapies for treatment or prevention of cancer. Also included are methods for screening for epitope-specific Integrin α V β 3 antagonists which can be used according to the methods of the invention. In addition, methods for facilitating the use of Integrin α V β 3 antagonists in the analysis of Integrin α V β 3 expression in biopsies of animal model and clinical study samples are also contemplated.
摘要翻译：本发明涉及用于治疗，管理或预防癌症的方法和组合物。本发明的方法包括单独施用有效量的一种或多种整合素αVβ3的拮抗剂，或与施用有效量的一种或多种其它可用于癌症治疗的试剂组合施用。本发明还提供包含一种或多种整合素αVβ3拮抗剂和/或一种或多种其它可用于癌症治疗的试剂的药物组合物。特别地，本发明涉及通过单独施用治疗或预防有效量的一种或多种整合素αVβ3拮抗剂或与用于治疗或预防癌症的标准和实验疗法组合来治疗和预防癌症的方法。还包括用于筛选可以根据本发明的方法使用的表位特异性整合素αVβ3拮抗剂的方法。此外，还考虑了促进在整合素αVβ3拮抗剂在动物模型和临床研究样品的活组织检查中分析整合素αVβ3表达的方法。

4. 发明申请

WO2005016381A3 COMBINATION THERAPY FOR THE TREATMENT AND PREVENTION OF CANCER USING EPHA2, PCDGF, AND HAAH 审中-公开
标题翻译：使用EPHA2，PCDGF和HAAH治疗和预防癌症的联合治疗
公开(公告)号：WO2005016381A3
公开(公告)日：2006-02-09
申请号：PCT/US2004023097
申请日：2004-07-16
申请人： MEDIMMUNE INC , KINCH MICHAEL S , CARLES-KINCH KELLY , KIENER PETER , LANGERMANN SOLOMON , MCCARTHY MICHAEL P , TICE DAVID , WOESSNER RICHARD
发明人： KINCH MICHAEL S , CARLES-KINCH KELLY , KIENER PETER , LANGERMANN SOLOMON , MCCARTHY MICHAEL P , TICE DAVID , WOESSNER RICHARD
IPC分类号： A61K39/395 , C07K16/28 , C07K16/30 , C07K16/40 , A61P35/04
CPC分类号： C07K16/40 , A61K39/39558 , A61K2039/505 , C07K16/3076 , C07K2317/73 , C07K2317/75 , C07K2317/80 , A61K2300/00
摘要： The present invention relates to methods and compositions designed for the treatment, management, or prevention of a hyperproliferative disorder, particularly cancer, more particularly metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more agents that decrease/inhibit EphA2 expression or activity in combination with one or more agents that decrease/inhibit PCDGF or HAAH expression or activity. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2, PCDGF, and/or HAAH agents of the invention that inhibit cancer cell colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparation. The invention also provides pharmaceutical compositions comprising one or more EphA2 agents of the invention in combination with one or more PCDGF agents of the invention and/or one or more HAAH agents of the invention. In some embodiments, the agents of the invention can be administered with other cancer therapeutic agents that are not EphA2-, PCDGF-, or HAAH-based. Diagnostic methods and methods for screening for therapeutically useful agents of the invention are also provided.
摘要翻译：本发明涉及设计用于治疗，控制或预防过度增殖性疾病，特别是癌症，特别是转移性癌症的方法和组合物。本发明的方法包括给予一种或多种降低/抑制EphA2表达或活性的一种或多种与减少/抑制PCDGF或HAAH表达或活性的一种或多种试剂组合的试剂。在另一个实施方案中，本发明的方法包括施用有效量的本发明的一种或多种EphA2，PCDGF和/或HAAH剂，其抑制在三维基底中的软琼脂或管状网络形成中的癌细胞集落形成膜或细胞外基质制剂。本发明还提供包含本发明的一种或多种EphA2试剂与本发明的一种或多种PCDGF试剂和/或本发明的一种或多种HAAH试剂组合的药物组合物。在一些实施方案中，本发明的药剂可以与不是EphA2-，PCDGF-或HAAH的其它癌症治疗剂一起施用。还提供了用于筛选本发明的治疗有用的药剂的诊断方法和方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式